DiaSorin

Healthy Q2 and H1; resulting in consecutive guidance upgrade

04/08/22 -"DiaSorin released healthy Q2 results. While, as expected, non-COVID-19 offerings continued to do well, slower-than-expected moderation in COVID-19 testing sales was a pleasant surprise – also ..."

PDF page sample
Pages
62
Language
English
Published on
04/08/22
Download
You may also be interested by these reports :
07/07/25
Sartorius (BUY; Germany), a historically pristine business, has fallen off its perch. Following the big and expensive bet on Polyplus, Sartorius ...
04/07/25
We’ve updated our forecasts to reflect the latest asset disposals, including Baywater (expected to generate €60m revenue in FY24/25 ending June ...
04/07/25
Among Europe’s holding companies, Exor (BUY; Netherlands) is one of the rare, truly active stewards of capital: unafraid to rotate its portfolio, ...
24/06/25
FMC has expanded its savings goals beyond the FME25 programme, targeting approximately €750 million in savings by 2025, with an additional €300m by ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO